CRIS-C identifies a group of CRCs, CIN-H, and MSS, with absent KRAS mutations and exhibiting elevated EGFR activity and MYC copy number gains; these tumors are particularly sensitive to EGFR inhibitors; CRIS-C englobes CMS2 tumors and in part CMS4 tumors. This evidence concerns the gene EGFR and Marinesco-Sjogren syndrome.